B. Riley Upgrades Core Scientific as CoreWeave Deal Faces Growing Opposition
B. Riley raises Core Scientific price target to $30, predicting shareholders will vote down CoreWeave's $9B offer. Glass Lewis and ISS recommend voting against.
NOTRELOAD AI
Alkermes to Acquire Avadel for Up to $2.1 Billion, Expanding Into Sleep Medicine Market
Alkermes (ALKS) announces $2.1B acquisition of Avadel Pharmaceuticals (AVDL) to gain approved narcolepsy drug Lumryz and enter the growing sleep medicine market. Deal expected Q1 2026.
JPMorgan Downgrades HP Stock: What Investors Need to Know
JPMorgan cuts HP Inc. rating to Neutral as PC replacement cycle ends and growth challenges emerge.
AT&T Beats Expectations with Strong Customer Growth Despite Heavy Competition
AT&T surpasses analyst predictions by adding 405,000 mobile subscribers and 288,000 fiber customers in Q3 2025, driven by aggressive promotions and bundled service offerings.
Alector Cuts Half Its Workforce After Failed Dementia Drug Trial
Alector announces 49% workforce reduction and discontinuation of latozinemab trials after Phase 3 study fails to show clinical benefit in frontotemporal dementia patients.
Terns Pharma Abandons Obesity Drug After Disappointing Trial Results
Terns Pharmaceuticals halts development of oral GLP-1 obesity treatment TERN-601 after Phase 2 trial shows modest weight loss and liver safety concerns.